At what enterprise value was OTIOM acquired in 2025?

During the acquisition of OTIOM by PHARMA EQUITY GROUP in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 10M - 30M DKK. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of OTIOM when it was acquired by PHARMA EQUITY GROUP?

The exact EV/EBITDA multiple for OTIOM is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was OTIOM acquired by PHARMA EQUITY GROUP?

OTIOM was acquired by PHARMA EQUITY GROUP in 2025.

What was the revenue of OTIOM at the time of the deal?

The revenue of OTIOM at the time of the deal is estimated to be in the range of 5M - 25M DKK. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the OTIOM acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OTIOM deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://ml-eu.globenewswire.com/Resource/Download/575b8a3a-14e4-40b4-95b0-23bcba7467ee

← DATABASE

Home Database Healthcare & PharmaOTIOM

12/2025

PHARMA EQUITY GROUP takes majority stake in OTIOM

DENMARK Healthcare Services / Health Tech EV 10M - 30M DKK

Context

Pharma Equity Group A/S is acquiring Otiom A/S. The transaction follows the signing of a Letter of Intent in December 2025, under which PEG intends to purchase either the entire share capital or a controlling stake in the Danish MedTech firm. Otiom, which operates a patented IoT localisation platform for dementia care, currently supplies its technology in twenty‑four countries and maintains a network of thirteen EU distributors. The acquisition represents PEG’s first entry into a commercial MedTech business complementary to its pharmaceutical activities. The acquisition aligns with PEG’s strategy to broaden its portfolio with assets that have shorter commercial timelines than traditional drug development. Otiom’s established market presence, validated technology and near break‑even cash‑flow provide an immediate revenue stream and a platform for geographic scaling. PEG’s expertise in capital markets, regulatory navigation and strategic management is intended to accelerate Otiom’s expansion into additional European markets and to deepen its product offering through integration with existing portfolio resources. Post‑closing, Otiom’s management is expected to remain operationally engaged while PEG issues new shares to the sellers, creating a shared ownership structure. The combined entity aims to leverage centralized strategic governance with decentralized execution, targeting increased unit sales, higher subscription uptake and enhanced data analytics capabilities. Anticipated synergies include shared procurement, joint research on sensor technologies and coordinated sales efforts, which are projected to improve cash‑flow generation and strengthen PEG’s position in the Nordic health‑technology landscape.

OTIOM, which reported an EBITDA margin of LOGIN in 2026, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Otiom A/S is a Danish medical technology company that develops and commercialises an Internet of Things based localisation solution for individuals living with dementia. The system combines wearable sensors with cloud‑based analytics to generate real‑time positioning data and alarm notifications for caregivers and family members. Devices are sold to care facilities, municipal health services and private users, generating recurring revenue through hardware sales and subscription fees for data services. The technology is protected by a patent covering the sensor architecture and data processing algorithm. Otiom operates a distribution network that includes thirteen authorised partners across the European Union and supplies its units to customers in twenty‑four countries. In its home market the company holds a top‑three market position, and it reports strong uptake in the DACH and Nordic regions. Production volumes exceed nine‑thousand units, and the platform processes more than eight‑thousand active events per week, demonstrating operational scalability. The business model relies on a combination of upfront equipment pricing and ongoing service contracts, allowing the firm to maintain a cash‑flow profile close to break‑even while expanding its installed base. Research and development activities focus on enhancing sensor accuracy, battery life and integration with third‑party care management software. Otiom’s corporate structure includes a board of directors and a management team that remains actively involved post‑investment.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (DKK)

Year

Rev

EBITDA

EBIT

2026

2025

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services	Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Healthcare Services	TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority
11/2025	EURAZEO	EXCELYA	FRANCE	Healthcare Services	The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Healthcare Services	Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
05/2025	FIVE ARROWS	HUBLO	FRANCE	Healthcare Services	Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group
04/2025	KERSIA	NEOGEN (ANIMAL BIOSECURITY DIVISION)	UNITED STATES	Healthcare Services	Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services	Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest

REFERENCES

Valuation range: EV 10M - 30M DKK

Revenue range: 5M - 25M DKK

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OTIOM by PHARMA EQUITY GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: pharma equity group